Citadel Advisors’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Citadel Advisors’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-35,706	Closed	-$2.28K	–	16143
2022 Q4	$2.28K	Sell	35,706 -35,689	-50%	-$1.36K	﹤0.01%	14354
2022 Q3	$4K	Sell	71,395 -1,408	-2%	-$82	﹤0.01%	12399
2022 Q2	$3K	Sell	72,803 -425,310	-85%	-$87.9K	﹤0.01%	12714
2022 Q1	$117K	Buy	498,113 +400	+0.1%	+$128	﹤0.01%	12117
2021 Q4	$323K	Sell	497,713 -175,149	-26%	-$122K	﹤0.01%	10764
2021 Q3	$444K	Buy	672,862 +49	+0%	+$36	﹤0.01%	10172
2021 Q2	$578K	Buy	672,813 +224,996	+50%	+$156K	﹤0.01%	9730
2021 Q1	$273K	Buy	+447,817	New	+$316K	﹤0.01%	11057

Citadel Advisors's BIOTW Position: Q1 2023 in Review

Citadel Advisors sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 35,706 shares — an estimated $2.28K sold.

Citadel Advisors first reported a position in BIOTW in Q1 2021 and held it in 8 quarters. The position peaked at $578K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Citadel Advisors reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Citadel Advisors sold 35,706 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $2.28K.
Citadel Advisors first reported a position in Biotech Acquisition Company Warrant in Q1 2021 and held it in 8 quarters.
Citadel Advisors's Biotech Acquisition Company Warrant position peaked at $578K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.